E01F0002 Human Free Fatty Acid ELISA kit
The Human Free Fatty Acid ELISA kit can be used to identify samples from the human species. Free Fatty Acid can also be called FFA, NEFA, nonestesterified fatty acid, Non-Esterified Fatty Acid, free fatty acid.
Product Information | |
Cat. No. | E01F0002 |
Product Name | Human Free Fatty Acid ELISA kit |
Species | Human |
Product Size | 48 Tests / 96 Tests |
Concentration | 50-1000 ug/ml |
Sensitivity | 1.0 ug/ml |
Principal | Competitive ELISA |
Sample Volume | 100 ul |
Sample Type | Serum, plasma, cell culture supernatants, body fluid and tissue homogenate |
Assay Time | 90 minutes |
Platform | Microplate Reader |
Conjugate | HRP |
Detection Method | Colorimetric |
Storage | 2-8°C |
Kit Components | ||
MATERIALS | SPECIFICATION | QUANTITY |
MICROTITER PLATE | 96 wells | stripwell |
ENZYME CONJUGATE | 10.0 mL | 1 vial |
STANDARD A (0.5mL) | 0 ug/mL | 1 vial |
STANDARD B (0.5mL) | 50 ug/mL | 1 vial |
STANDARD C (0.5mL) | 100 ug/mL | 1 vial |
STANDARD D (0.5mL) | 250 ug/mL | 1 vial |
STANDARD E (0.5mL) | 500 ug/mL | 1 vial |
STANDARD F (0.5mL) | 1000 ug/mL | 1 vial |
SUBSTRATE A | 6 mL | 1 vial |
SUBSTRATE B | 6 mL | 1 vial |
STOP SOLUTION | 6 mL | 1 vial |
WASH SOLUTION (100 x) | 10 mL | 1 vial |
BALANCE SOLUTION | 3 mL | 1 vial |
Principle of the Assay |
FFA ELISA kit applies the competitive enzyme immunoassay technique utilizing an anti-FFA antibody and an FFA-HRP conjugate. The assay sample and buffer are incubated together with FFA-HRP
conjugate in pre-coated plate for one hour. After the incubation
period, the wells are decanted and washed five times. The wells are then
incubated with a substrate for HRP enzyme. The product of the
enzyme-substrate reaction forms a blue colored complex. Finally, a stop
solution is added to stop the reaction, which will then turn the
solution yellow. The intensity of color is measured
spectrophotometrically at 450nm in a microplate reader. The intensity of
the color is inversely proportional to the FFA concentration since FFA from samples and FFA-HRP conjugate compete for the anti-FFA antibody binding site. Since the number of sites is limited, as more sites are occupied by FFA from the sample, fewer sites are left to bind FFA-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The FFA concentration in each sample is interpolated from this standard curve. |
Coefficient of Variance | Intra Variation% ＜10% | |
Inter Variation% ＜12% | ||
Recovery | 95-102% | |
Linearity | Diluent Ratio | Range % |
1:2 | 93-105 | |
1:4 | 88-106 | |
1:8 | 86-108 | |
Specificity/Cross-reactivity | No significant cross-reactivity or interference between FFA and analogues was observed. | |
E01F0002 has been referenced in the below publications：
Correlation of FFA, UCP-1 level and obesity in T2DM patients.
Related Bluegene Biotech Products
BlueGene Biotech News
